Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
BASIC RESEARCH
You have accessRestricted Access

Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells

Pietro Cirillo, Michael S. Gersch, Wei Mu, Philip M. Scherer, Kyung Mee Kim, Loreto Gesualdo, George N. Henderson, Richard J. Johnson and Yuri Y. Sautin
JASN March 2009, 20 (3) 545-553; DOI: https://doi.org/10.1681/ASN.2008060576
Pietro Cirillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael S. Gersch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Mu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip M. Scherer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyung Mee Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loreto Gesualdo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George N. Henderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuri Y. Sautin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Increased consumption of fructose may play an important role in the epidemic of metabolic syndrome and may presage the development of diabetes, cardiovascular disease, and chronic kidney disease. Once in the cell, fructose is phosphorylated by ketohexokinase (KHK), leading to consumption of ATP, formation of AMP, and generation of uric acid through xanthine oxidoreductase (XOR). This study aimed to examine the direct effects of fructose in human kidney proximal tubular cells (HK-2) and whether they are mediated by the fructose metabolism via KHK. At a similar concentration to that observed in peripheral blood after a meal, fructose induced production of monocyte chemotactic protein 1 (MCP-1) and reactive oxygen species in HK-2 cells. Knockdown of KHK by stable transfection with small hairpin RNA demonstrated that these processes were KHK dependent. Several antioxidants, including specific inhibitors of NADPH oxidase and XOR, prevented MCP-1 secretion. We detected XOR mRNA in HK-2 cells and confirmed its activity by identifying uric acid by mass spectrometry. Fructose increased intracellular uric acid, and uric acid induced production of MCP-1 as well. In summary, postprandial concentrations of fructose stimulate redox- and urate-dependent inflammatory mediators in proximal tubular cells.

Metabolic syndrome, characterized by visceral obesity, insulin resistance, elevated BP, hypertriglyceridemia, and microalbuminuria,1,2 is strongly associated with the development of type 2 diabetes, cardiovascular disease, and all-cause mortality.3–6 The prevalence of metabolic syndrome has been increasing worldwide during the past decades.7,8 Several epidemiologic9–12 and experimental studies12–14 reported that increased consumption of fructose, which is ubiquitous in modern Western diets, may play an important role in the development of the current epidemic of metabolic syndrome in addition to lack of exercise, overnutrition, and genetic predisposition. Fructose is a monosaccharide normally present in fruit and vegetables and in table sugar (sucrose); however, the majority of dietary fructose intake in the United States comes from high-fructose corn syrup, a widely used sweetener. Clinical studies showed that fructose intake can induce hypertriglyceridemia, weight gain, increased BP, and hyperuricemia.15–17

In humans, fructose is absorbed unchanged in the small intestine followed by transport to the liver, which metabolizes ≥50% of the total absorbed fructose with the remainder taken up primarily by the kidney and adipose tissue.18,19 Fructose enters cells predominantly through the transporters GLUT5 and/or GLUT2. Both transporters are expressed in the kidney, mostly in the proximal tubule. In the liver, as well as in the kidney, fructose is phosphorylated by fructokinase (ketohexokinase [KHK]) to yield fructose-1-phosphate followed by cleavage by aldolase B to dihydroxyacetone phosphate and glyceraldehyde.20,21 Fructose can also be phosphorylated by hexokinase, but the Km for fructose is much higher than for glucose, which minimizes fructose phosphorylation through this pathway.19

Unlike hexokinase, the KHK pathway of fructose metabolism bypasses tightly regulated glycolytic checkpoints, especially phosphofructokinase. Because KHK has no negative feedback, all fructose entering the cell is rapidly phosphorylated, which can result in ATP depletion, which has been well documented in vitro and in vivo in animal models and humans.22,23 ATP depletion activates enzymes of purine metabolism, which degrade adenine nucleotides to uric acid via xanthine oxidoreductase (XOR)19–21 with the development of hyperuricemia.21,19 KHK is expressed predominantly in the liver, small intestine, and kidney.24–26 The highest KHK activity along the nephron is present in the proximal tubule.27

Our group showed recently that fructose consumption can accelerate the progression of chronic kidney disease (CKD) in the rodent remnant kidney model.28 A fructose-rich diet enhanced glomerulosclerosis, tubular atrophy, tubulointerstitial inflammation, interstitial collagen deposition, and peritubular monocyte-macrophage infiltration.28 Control rats fed equal amounts of a starch (glucose)-based diet showed significantly less progression. Although the effects of fructose may be mediated by some components of the metabolic syndrome such as dyslipidemia and hyperinsulinemia, tubular epithelial cells express fructose transporters and KHK, which may target these cells for direct effects of fructose. We therefore performed an in vitro study using human epithelial tubular cells (HK-2) to examine the effects of fructose in these cells and determine potential mechanisms by which fructose may induce tubular damage and whether they involve KHK.

RESULTS

KHK-Mediated Monocyte Chemotactic Protein 1 Production Induced by Fructose

Our group reported previously that a high-fructose diet increases the renal expression of monocyte chemotactic protein 1 (MCP-1) in the remnant kidney model of rats and confirmed this effect in vitro in HK-2 cells.28 MCP-1 is a potent chemoattractant of monocytes/macrophages and plays a key role in the proinflammatory response,29 and its action is predominantly confined to the renal tubule, which is also a major site of production.30 MCP-1 has been shown to play a crucial role in the inflammatory-mediated renal damage.31 To explore this effect further in renal epithelial cells and to determine whether it occurs with physiologic concentrations of fructose, we stimulated HK-2 cells with various concentrations of fructose for 72 h and found that 1 mM fructose (equal to the physiologic postprandial concentration in the peripheral blood21) induced more than a two-fold increase in MCP-1 production (Figure 1A). Further increasing the fructose concentration to 5 and 10 mM plateaued with an additional 30% increment, statistically not different from the MCP-1 level at 1 mM. Interestingly, glucose did not stimulate MCP-1 (Figure 1B) and even attenuated the effect of fructose at the concentration 25 mM (Figure 1C). Stimulation of mannitol also did not induce an elevation of MCP-1 level excluding an osmotic mechanism (Figure 1D). When we compared the effects of fructose and tagatose, which is also metabolized by KHK,32 we found that both sugars, at 5 mM, induced a significant increase in MCP-1 production (Figure 1E), suggesting that MCP-1 release depends largely on the first step of fructose metabolism because tagatose, after phosphorylation by KHK, is metabolized much slower than fructose-1-phosphate.32

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Fructose-induced MCP-1 production in HK-2 cells. (A) Dosage-dependent effect of fructose on MCP-1 production. Glucose content in the medium in this and other experiments unless indicated otherwise was 5 mM. (B) Difference in the effects of fructose and glucose on MCP-1 production. (C) Glucose attenuates effect of fructose on MCP-1 production. (D) d-Mannitol did not produce a significant effect on MCP-1 production, excluding the osmotic mechanism. (E) Similarity of the effects of fructose and tagatose on MCP-1 production. In all experiments, cells were treated with fructose, glucose, tagatose, and mannitol for 72 h. MCP-1 content in the medium was assayed by ELISA and is expressed as pg/mg of cellular protein content. Data are means ± SEM *P < 0.05 versus untreated cells or corresponding control, nonparametric U test and, in A, one-way ANOVA; #P = 0.06 versus 5 mM fructose + 5 mM glucose; n = 3, each experiment performed in triplicate.

Because KHK expression in the kidney and, specifically, in the proximal tubule is very high, we next sought whether metabolism by KHK is required for the proinflammatory effect of fructose to induce MCP-1 production. First, we detected expression of KHK in HK-2 cells and found that mRNA for KHK in these cells is expressed at a level comparable to the liver (Figure 2A). Next, we transfected HK-2 with four different small hairpin RNA (shRNA) constructs for human KHK containing a gene coding resistance to puromycin and used this latter property to select stably transfected clones in puromycin-containing medium. Among the resistant clones, two showed an almost absent expression of the mRNA for KHK (Figure 2B). Western blot analysis confirmed that >75% of the KHK expression was suppressed at the protein level (Figure 2C). Stable transfection of HK-2 cells with nonrelevant shRNA did not affect KHK expression showing the absence of nonspecific effects on transfection and expression of small interfering RNA duplexes in the cells (Figure 2, B and C). We also confirmed a reduction in the functional activity of KHK in the silenced clones as reflected by the absence of ATP depletion in response to fructose (Figure 2D) because ATP depletion by acute fructose loading is strictly KHK dependent.22,23,33 That an increase in ATP was seen after fructose loading in these clones (Figure 2D) is because, in the absence of KHK, fructose enters the glycolytic cascade via hexokinase, resulting in an increase in net ATP production. Next, we incubated nontransfected HK-2 cells, KHK-silenced HK-2 clone, and cells stably expressing a nonrelevant shRNA with fructose. To obtain a robust response, we used a concentration of fructose 5 mM. In nontransfected cells and pRS-GFP shRNA clone, fructose induced MCP-1 production, whereas stable silencing of KHK abolished the effect of fructose even at 5 mM, indicating a specific requirement for KHK (Figure 2E).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

KHK is required for fructose-induced MCP-1 production in HK-2 cells. (A) Expression of mRNA for KHK and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in HK-2 cells and human liver. Inverted images of the RT-PCR products on agarose gel are shown. (B) mRNA expression for KHK and GAPDH genes in nontransfected HK-2 cells and puromycin-resistant clones transfected with pRS-GFP and pRS-KHK. (C) Analysis of KHK silencing at the protein level. Representative blot and densitometric analysis (KHK/GAPDH ratio) are shown. (D) Functional test of KHK silencing: Effect of fructose on KHK-dependent ATP depletion. (E) Fructose-induced MCP-1 is abolished by KHK silencing. Cells were treated with fructose for 72h. MCP-1 content in the medium was assayed by ELISA and is expressed as pg/mg of cellular protein content or percentage of control (100%). *P < 0.05 versus untreated cells or corresponding control, nonparametric U test; n = 3, each experiment performed in triplicate.

Involvement of Reactive Oxygen Species in the KHK-Mediated MCP-1 Production Induced by Fructose

MCP-1 production can be blocked by antioxidants in proximal tubular cells and other cells.34,35 We therefore examined fructose-induced MCP-1 production in the presence of antioxidants N-acetylcysteine, cell-permeable superoxide scavenger MnTMPyP, and inhibitors of NADPH oxidase (apocynin) and xanthine oxidoreductase (allopurinol). All tested antioxidants completely abrogated the effect of fructose, suggesting that fructose-induced MCP-1 stimulation in HK-2 cells is redox dependent and mediated by superoxide production (Figure 3A). Apocynin suppressed both basal and stimulated reactive oxygen species (ROS) production (Figure 3A).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Fructose-induced KHK-dependent MCP-1 production in HK-2 cells is mediated by ROS (A) Fructose-dependent MCP-1 increase is prevented by antioxidants [10 mM N-acetyl-cysteine (NAC), 25 μM Mn(II) tetrakis(1-methyl-4 to 6 pyridyl) porphyrin (MnTMPyP), 0.1 mM allopurinol, and 200 μM apocynin]. Cells were treated for 72 h. (B) ROS production by HK-2 cells in the presence of 5 mM fructose. ROS-induced fluorescence is shown on the left, and differential interference contrast (DIC) is shown on the right. Cells were treated with fructose for 2 h. (C) Dosage response of ROS production in HK-2 cells incubated with varying concentrations of fructose or d-mannitol for 2 h. (D) Time course of ROS production in HK-2 cells incubated in 5 mM fructose. The antioxidant tempol (5 mM) completely prevented an increase in the fluorescence in response to fructose, demonstrating specificity of ROS detection (data not shown). (E) ROS accumulation after 2 h of stimulation with 5 mM fructose in nontransfected HK-2 and HK-2 clones stably expressing KHK shRNA or GFP-shRNA as a control for irrelevant shRNA and transfection. (F) Effect of oxypurinol (0.1 mM) on fructose-induced ROS production. Data are expressed as arbitrary units of fluorescence and are means ± SEM (n = 3 performed in triplicate, each representing 20 to 30 cells). *P < 0.05 versus untreated cells or corresponding control; &P < 0.05 versus fructose-treated cells, nonparametric U test.

These results prompted us to examine the effect of fructose on ROS production in HK-2 using live cell imaging with the ROS-specific fluorescence probe 5 (and 6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate-acetyl ester (CM-H2DCFDA). As shown in Figure 3B, fructose induced an increase in the probe fluorescence, which was ROS specific because the antioxidant tempol prevented this increase (data not shown). At concentrations of 0.5 to 5.0 mM, fructose-induced ROS production was dose dependent. An increase in oxidants was observed with concentrations as low as 1 mM (physiologic) and reached a plateau between 5 and 10 mM (Figure 3C). In the presence of d-mannitol, ROS production was not affected (Figure 3C), excluding an osmotic mechanism in the effect of fructose. Time-course experiments showed that the level of ROS increased as early as 15 min and remained at the same level for approximately 4 h with return to basal levels after 16 h, when, most likely, all of the added fructose was metabolized (Figure 3D).

To test whether fructose-induced ROS production was KHK dependent, we incubated nontransfected cells, KHK-silenced HK-2 cells, and cells transfected with nonrelevant shRNA in the presence or absence of a high level of fructose (5 mM) for 2 h. Fructose produced a significant increase in ROS production in normal HK-2 and in pRS-GFP(−) clone cells, whereas no effect was observed in cells with silenced KHK expression (Figure 3E). Finally, to test whether fructose-induced ROS production is dependent on xanthine oxidoreductase (XOR) and urate production as suggested by results in Figure 3A, we tested the effect of fructose in the presence of oxypurinol (0.1 mM), a XOR inhibitor. Oxypurinol did not modify the level of ROS in untreated cells but partially reduced ROS accumulation in cells treated with 5 mM fructose, suggesting involvement of XOR in this pathway (Figure 3F).

XOR Expression and Uric Acid Production in Response to Fructose in Tubular Epithelial Cells

Fructose metabolism via KHK results in the stimulation of AMP-deaminase followed by a XOR-mediated increase in uric acid formation.36,37 This process has been usually studied in the liver; however, KHK is highly expressed in HK-2 cells and fructose-induced MCP-1 and ROS production might be suppressed by XOR inhibition. We therefore examined the expression of XOR in HK-2 cells and measured uric acid, the XOR reaction product. Reverse transcriptase–PCR (RT-PCR) analysis confirmed modest expression of XOR (Figure 4A). To identify uric acid, we used mass spectrometry. Uric acid was identified in the extract of HK-2 cells as fragments at m/z 124 and 96 by mass spectrometry (MS)/MS analysis as described in the Concise Methods section (Figure 4B), confirming that XOR is active. Next we tested whether fructose increases uric acid production in these conditions and whether uric acid is responsible for the increase in MCP-1 expression. Uric acid was measured in fructose-treated cells by both enzymatic assay with uricase and by MS. Figure 4, C and D, shows that fructose treatment induced an increase in intracellular level of uric acid in HK-2 cells that was completely prevented by allopurinol (Figure 4D). To determine whether fructose can induce local accumulation of uric acid in the kidney, we measured its content in the crude kidney homogenates from rats pair fed with the high-fructose diet or standard rat diet for 16 wk; however, in this case, we observed only a tendency to an increase in the uric acid content from 0.122 ± 0.025 to 0.145 ± 0.031 nmol/mg protein (P < 0.1; n = 6).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Fructose-induced intracellular uric acid production and XOR expression in HK-2 cells. (A) Expression of mRNA for XOR and β-actin in HK-2 cells. Inverted images of the RT-PCR products on agarose gel are shown. (B) Identification of uric acid in samples by MS/MS experiments. (C) Intracellular uric acid content in response to 1 and 5 mM fructose stimulation for 72 h. Data are means ± SEM and are expressed as nmol/mg of protein. *P < 0.05 versus untreated cells. (D) Analysis of the effect of fructose with and without allopurinol on the intracellular level of uric acid by tandem LC/MS/MS. Extracts contained the same amount of total protein. The x axis is the retention time, and the y axis is the intensity of the single-reaction monitoring peaks. The peak area is proportional to the quantity of uric acid.

Uric Acid Mimics the Effect of Fructose on MCP-1 Production

To test whether intracellular urate production induced by fructose affects MCP-1 production, we incubated cells with fructose with or without allopurinol (0.1 mM). As shown in Figure 5, allopurinol blocked fructose-induced MCP-1 production, suggesting that the fructose effect might be mediated by XOR-induced oxidants and/or increased uric acid production. Cell stimulation with 15 mg/dl uric acid mimicked the effect of fructose. Combining 5 mM fructose and 15 mg/dl uric acid, however, did not produce an additional effect on the MCP-1 levels, showing that effects of fructose and uric acid are not additive. The presence of 0.1 mM allopurinol in the latter combination partially reduced MCP-1 production, suggesting a partial involvement of XOR in this pathway (Figure 5).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Comparison of the effects of fructose and uric acid on MCP-1 production in HK-2 cells. Cells were treated with fructose and/or uric acid with or without allopurinol for 72 h. MCP-1 content in the medium was assayed by ELISA and is expressed as pg/mg of cellular protein. Data are means ± SEM; n = 3, each experiment is performed in triplicate. Statistical analysis was performed using nonparametric U test.

DISCUSSION

This study demonstrates that fructose exerts direct and potentially detrimental effects on cultured human proximal tubular epithelial cells. These cells, along with hepatocytes, adipocytes, and possibly endothelial cells, metabolize fructose via KHK, bypassing common checkpoints for carbohydrate metabolism.18–21 Fructose, at physiologic concentrations, induced proinflammatory mechanisms (MCP-1 synthesis) and oxidative stress in the proximal tubular cells. We further demonstrated that KHK, the first enzyme of the main pathway of fructose metabolism, is required for this redox-dependent proinflammatory effect.

The level of fructose in the peripheral blood38 and in the renal tubule27 in fasting conditions is usually very low (10 to 60 μM). Postprandial levels of fructose in the portal blood rise to 2.2 mM, and because the liver takes up 50 to 75% of absorbed fructose, postprandial levels in the peripheral blood are approximately 1 mM21 and depend on the amount and speed by which fructose and sugar are ingested.39 Upon fructose loading, its concentrations along the nephron may reach levels equaling or exceeding the concentration in peripheral blood.27 Thus, it is likely that the effects we observed in HK-2 cells could be physiologically relevant. It is noteworthy that levels as low as 1 mM were able to stimulate MCP-1, ROS, and uric acid production in our cellular system. Although we used higher concentrations (5 to 10 mM) in some experiments to get robust responses to help discern pathways, the response of HK-2 cells to supraphysiologic concentrations of fructose (5 to 10 mM) versus physiologic 1 mM was similar in character and magnitude.

We did observe that marked increases in glucose concentration (to 25 mM) could dampen the effect of fructose to induce MCP-1 production. Nevertheless, postprandial elevations in glucose are usually modest (5 to 8 mM). Furthermore, it is possible that the urinary concentration of fructose may be more important because GLUT5 is expressed on the apical membrane.40 Furthermore, after glomerular filtration, glucose is reabsorbed rapidly and almost completely by the upper segments of the proximal tubule, whereas fructose is reabsorbed predominantly in the S3 segment that expresses GLUT5.40 The fructose/glucose concentration ratio along the renal tubule from fructose-loaded rats is several-fold higher than in the plasma, suggesting a slower reabsorption rate for fructose in comparison with glucose.27 Thus, the glucose-induced effect to dampen the fructose-induced ATP depletion and MCP-1 expression will be reduced by the time fructose reaches the S3 segment. In turn, it is the S3 segment in the outer medullary stripe that is so commonly the site for chronic renal injury because the site is in a threshold region of borderline hypoxia.41 MCP-1 is an inflammatory cytokine that mediates macrophage accumulation in a variety of experimental models of CKD. Besides its known chemoattractive action, MCP-1 specifically confers an inflammatory phenotype to tubular cells (reviewed in31). The ability of fructose to stimulate this proinflammatory factor may account for how fructose may injure the tubules and contribute to progressive renal injury.

The mechanism described here most likely underlies the previously demonstrated ability of fructose to accelerate the progression of CKD in the remnant kidney model,28 in particular by worsening tubulointerstitial inflammation, collagen deposition, and tubular atrophy. Because the metabolic effects of parenteral fructose load in rats are mainly confined to the proximal tubule27 and all enzymes involved in fructose metabolism via KHK pathway were found in the human renal cortex,42 renal tubular cells may, indeed, play a key role in fructose-induced renal damage.

Our results showed that fructose triggers proinflammatory pathways in renal epithelial cells by inducing MCP-1 production, which was abolished by KHK silencing. The metabolism of fructose beyond aldolase was less critical than KHK because tagatose, which is phosphorylated by KHK but poorly metabolized further,32 also stimulated MCP-1 production. Because MCP-1 production was effectively inhibited by allopurinol and antioxidants, the proinflammatory activity of oxidative stress and/or uric acid play an important role downstream from KHK. Interestingly, experiments using the superoxide scavenger MnTMPyP revealed that fructose-induced ROS are mediated by generation of superoxide. The experiments with other antioxidants showed that KHK-dependent ROS production might involve two major sources: NADPH oxidase and XOR. The role of ROS34,43 and uric acid34 in mediating MCP-1 production is well established in several cells types. We also previously reported that both fructose28 and uric acid44 increase MCP-1 in the kidneys of rats. Our results suggesting an involvement of NADPH oxidase are also in agreement with an in vivo study demonstrating that ROS production by vascular and blood cells in fructose-fed rats increased simultaneously with expression of the NADPH oxidase subunit p22phox.45

It has been known since 196822 that phosphorylation of fructose by KHK may rapidly deplete ATP in the liver and kidney, with the most dramatic drop in the renal cortex.33 These processes are associated with an increase in the degradation of AMP to hypoxanthine, followed by conversion to uric acid by XOR.17,46 Although intracellular urate production, which was confirmed in our experiments by MS, is not unexpected, it was not, to the best of our knowledge, previously reported. Moreover, fructose-induced increase in uric acid production confirms activity of XOR. Consistent with these findings, we observed that KHK-mediated MCP-1 and ROS production after fructose stimulation was dependent on XOR. Because oxypurinol blocks uric acid synthesis and ROS formation by xanthine oxidase,47,48 the ROS production in response to fructose might be partially mediated either by XOR-dependent ROS or by uric acid. Despite being an antioxidant in the serum, uric acid can engage redox-dependent signaling in adipocytes with the production of oxidants by NADPH oxidase.49 Conversely, fructose feeding induced only a mild and NS increase in urate content in the kidney homogenates, suggesting that uric acid could be increased only in proximal tubular cells, where it is produced via a KHK-dependent mechanism, but not in other cell types, which do not express KHK.

In conclusion, our studies suggest that the intake of foods high in fructose content can induce proinflammatory changes in the proximal tubule through a direct KHK-dependent mechanism, with stimulation of MCP-1 and the induction of oxidative stress. These studies could provide a causal link between obesity and metabolic syndrome and the development of renal disease.

CONCISE METHODS

Cell Culture

HK-2, an immortalized cell line from normal adult human kidney that maintains phenotype of proximal tubular cells50 and represents the best in vitro model of human proximal tubule cells, were obtained from American Type Culture Collection (Rockville, MD). Cells were grown to confluence in DMEM/F-12 (50/50) with l-glutamine and HEPES buffer (Mediatech, Herndon, VA) supplemented with 10% FBS; 100 U/ml penicillin; 100 g/ml streptomycin; and 2 mM l-glutamine and insulin (10 mg/L), transferrin (5.5 mg/L), and sodium selenite (6.7 μg/L). Cells were cultured at 37°C in 95% air and 5% carbon dioxide (CO2) to 70 to 75% of confluence.

Animal Protocol

All animal protocols were approved by the University of Florida Institutional Animal Care and Use Committee. Twenty-four 150-g male Sprague-Dawley rats (Charles Rivers Laboratories, Wilmington, MA) were divided into four groups of six rats each and received a diet of either 60% fructose (F60) or standard rat food (control), which contains complex carbohydrates, instead of purified sugars (Harlan-Teklad, Madison, WI). The animals were pair fed to ensure equal food intake. Rats were maintained in temperature- and humidity-controlled specific pathogen–free conditions on a 12:12-h light-dark cycle. After 16 wk, the rats were anesthetized with isoflurane and killed. Samples of the kidney tissues were stored at −80°C until analysis.

Stable Transfection of HK-2 Cells and KHK Silencing with shRNA

For the silencing of KHK in HK-2 cells, we used HuSH shRNA KHK-specific constructs in the pRS backbone under control of U6 promoter (Origene, Rockville, MD). To achieve long-term silencing, we used stable transfection. Cells were transfected with plasmids for four different KHK shRNA and shRNA for nonrelevant gene (GFP; pRS-GFP) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the protocol of the manufacturer followed by the selection of the transfectants resistant to puromycin in the selective medium containing 1 μg/ml puromycin for 8 to 10 wk. The best KHK-silenced clones were selected and validated on the basis of the lowest KHK mRNA expression and the absence of the functional KHK activity (see Figure 2). KHK-silenced HK-2 clone selected for experiment (pRS-KHK) and the clone stably expressing nonrelevant shRNA were maintained in the medium with 0.5 μg/ml puromycin, which was removed before experiments.

RNA Isolation and RT-PCR

Total RNA extraction was performed with TRIZOL (Invitrogen). The RNA purity and concentration were evaluated by spectrophotometric measurements. KHK was detected in normal HK-2 and in clones using SuperScript One-Step RT-PCR with Platinum Taq System (Invitrogen) according to the protocol of the manufacturer with the following primers: KHK (Genebank NM_006488; 89 bp, fully compatible with KHK-A and KHK-C isoforms), forward primer 5′-TCATGGAAGAGAAGCAGATCC-3′ and reverse primer 5′-CTCCGAGTCCTCCTTAGGGTA-3′; glyceraldehyde-3-phosphate dehydrogenase (Genbank NM_002046; 355 bp), forward primer 5′-TCACCAGGGCTGCTTTTAAC-3′ and reverse primer 5′-TTCACACCCATGACGAACAT-3′; and XOR (Genbank NM_000379), forward primer 5′-CCTCCGCACAGATATTGTCAT-3′ and reverse primer 5′-GGGATCTTGTAGGTGCTAGGG-3′. The following cycling conditions were used for cDNA synthesis and PCR amplification: (1) Reverse transcription at 50°C for 30 min, (2) predenaturation at 94°C for 2 min, (3) denaturation at 94°C for 30 s, (4) annealing 57°C for 1 min, and (5) extension of primers at 72°C for 1 min. Steps 3 through 5 were repeated for 30 cycles. For DNA final extension, the products were held at 72°C for 5 min. The DNA fragments were separated by electrophoresis on 1.5% agarose gel with ethidium bromide (1 μg/ml) and then visualized by ultraviolet light. Total RNA form human liver used in this study was obtained from Ambion (Austin, TX).

Measurement of Intracellular ATP Content

Cellular ATP was measured by using an ATP bioluminescence assay (Roche assay kit CLS II; Roche, Mannheim, Germany), following the manufacturer's instructions. After the experimental treatments, cells were washed with ice-cold PBS and detached from the culture plates with 0.05% trypsin/0.02% EDTA, and then we added to the cell suspension boiling 200 mM Tris/8 mM EDTA (pH 7.75) solution and incubated for 2 min at 98°C. Cell debris was precipitated at 10,000 × g for 2 min. Then ATP was determined in the supernatant by adding luciferin/luciferase by automated injection in a luminometer (Optocomp II; MGM Instruments, Hamden, CT) with integration of the light signal for 2 s. The ATP concentration was calculated by interpolation from a standard curve. Cellular protein content was determined by using the BCA protein assay. The ATP content was normalized to protein concentration and was expressed as nanomoles per milligram of protein.

Uric Acid Assay

To assess intracellular uric acid content, we rinsed cells with ice-cold PBS and harvested them in buffer containing 25 mM HEPES (pH 7.1), 100 mM KCl, 1 mM dithiothreitol, and 0.1 mM EDTA. The cell extracts were homogenized by 100 strokes of the pestle and frozen/thawed in liquid nitrogen three to four times. The intracellular level of uric acid was measured using Amplex Red UA/Uricase Assay Kit from Invitrogen-Molecular Probes (Eugene, OR). The fluorescence was measured using excitation in the range of 530 to 560 nm and emission detection at approximately 590 nm. Uric acid concentration in the samples was determined from the standard curve. The uric acid levels were normalized for protein concentration and expressed as nanomoles per milligram of protein.

Detection of Uric Acid by MS

All samples were stored at −80°C before analysis. Before the analysis, they were thawed in a cold water bath and filtrated through a 0.2-μm Micro Centrifuge Nylon filter (Millipore, Billerica, MA) by centrifugation for 10 min at 14,000 rpm. The filtrates were sealed in amber glass vials using Teflon-lined caps for liquid chromatography (LC)-MS analysis. The calibrators were 0.050, 0.125, 0.250, 0.500, 1.000, and 5.000 μM uric acid in aqueous solution.

The LC-MS analyses were carried out with a ThermoFinnigan Surveyor liquid chromatography system (ThermoFinnigan, San Jose, CA) and a TSQ Quantum triple quadruple mass spectrometer (ThermoFinnigan) equipped with ESI interface operated in negative-ion mode. LC analyses were performed in a gradient elution mode using Phenomenex Luna 5μ C18 (2) 100A (150 mm × 4.6 mm) column (Phenomenex, Torrance, CA) coupled with a Phenomenex Luna C18,(2)5-μm particle size guard column. The mobile phase used included 5 mM ammonium acetate/0.1% acetic acid (A) and methanol (B). The mobile phase flow was 600 μl/min, and the sample injection volume was 20 μl. The gradient began at 95% A. The composition was linearly ramped to 25% B over the next 4.5 min, and it was maintained constant for 1.5 min. Then, it was reversed to the original composition of 95% A over 0.5 min, after which time it was kept constant for 0.5 min to reequilibrate the column. In the TSQ Quantum, nitrogen was used for both the sheath (60 psi) and auxiliary (20 units) gases. The heated capillary temperature was maintained at 350°C. The collision pressure was 1.5 U, and collision energy was 25 V. The single-reaction monitoring method was applied for the analysis. The ions selected for single-reaction monitoring were m/z 124.1 and 96.1. The operation of the LC-MS and data analysis were performed using ThermoFinnigan Xcalibur 1.4 software. The calibration was linear with the R2 value of 0.998.

ROS Detection

We assessed intracellular ROS with the fluorescence probe CM-H2DCFDA (Molecular Probes) as described previously in detail.49 Briefly, at the end of treatments, cells were washed with HBSS followed by incubation in the presence of CM-H2DCFDA (5 μM) for 30 min in HBSS. Then cells were transferred to HBSS without probe, and green fluorescence was measured using an inverted microscope Axiovert 200 (Carl Zeiss Microimaging, Thornwood, NY) equipped with CCD camera and image acquisition/analysis software AxioVision 4.5 (Carl Zeiss Microimaging, Thornwood, NY).

ELISA for MCP-1

At the end of the treatments, media supernatants were collected, quantified, and centrifuged at 1000× g for 10 min to remove dead and nonadherent cells, and the remnant cell monolayer was lysed as described for protein determination. MCP-1 content in the supernatant was assayed by human MCP-1/CCL2 immunoassay Quantikine kit (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. Experiments were performed in triplicate and confirmed on three independent occasions. The MCP-1 content was normalized to protein content and was indicated as picograms per milligram of protein.

Statistical Analysis

At least three independent experiments were performed in triplicate each. Data were analyzed by one-way ANOVA followed by Fisher least significant test, unpaired t test, or Mann-Whitney U test, with P < 0.05 considered significant. Comparison between two values was performed by t test or U test. ANOVA was used to test differences among several means.

DISCLOSURES

R.J.J. and Y.S. are listed as inventors on patent applications by the University of Florida related to the role of fructose in hypertension and metabolic syndrome. R.J.J. has also written a book on fructose for the lay public (Rodale Press, 2008).

Acknowledgments

This work was supported by Italian Society of Nephrology postdoctoral fellowship (P.C.), National Institutes of Health grant HL-68607 (R.J.J.), and the Gatorade Foundation (Y.S.).

We thank Dr. David T. Bonthron (University of Leeds, Leeds, UK) for helpful discussions and for providing plasmids of human KHK. We are also thankful to Dr. Eustacchio Montemurno for technical assistance in performing MCP-1 assay.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related editorial, “The Not-so-Sweet Side of Fructose,” on pages 457–459.

  • Copyright © 2009 by the American Society of Nephrology

References

  1. ↵
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 : 3143– 3421, 2002
    OpenUrlFREE Full Text
  2. ↵
    Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus, Geneva, World Health Organization, September 29, 2007. Available at: http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf. Accessed February 18, 2008
  3. ↵
    Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156 : 1070– 1077, 2002
    OpenUrlCrossRefPubMed
  4. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, Zaccaro D, Bergman RN, Savage PJ, Haffner SM: Insulin resistance and hypertension: The Insulin Resistance Atherosclerosis study. Hypertension 43 : 1324– 1331, 2004
    OpenUrlAbstract/FREE Full Text
  5. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 : 683– 689, 2001
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 : 2709– 2716, 2002
    OpenUrlCrossRefPubMed
  7. ↵
    Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 : 2444– 2449, 2004
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 : 1066– 1076, 2004
    OpenUrlCrossRefPubMed
  9. ↵
    Bray GA, Nielsen SJ, Popkin BM: Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79 : 537– 543, 2004
    OpenUrlAbstract/FREE Full Text
  10. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ: Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76 : 911– 922, 2002
    OpenUrlAbstract/FREE Full Text
  11. Beck-Nielsen H, Pedersen O, Lindskov HO: Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr 33 : 273– 278, 1980
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, Sanchez-Lozada LG: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 86 : 899– 906, 2007
    OpenUrlAbstract/FREE Full Text
  13. Hwang IS, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 10 : 512– 516, 1987
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290 : F625– F631, 2006
    OpenUrlCrossRefPubMed
  15. ↵
    Raben A, Vasilaras TH, Moller AC, Astrup A: Sucrose compared with artificial sweeteners: Different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. Am J Clin Nutr 76 : 721– 729, 2002
    OpenUrlAbstract/FREE Full Text
  16. Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 292 : 927– 934, 2004
    OpenUrlCrossRefPubMed
  17. ↵
    Gao X, Qi L, Qiao N, Choi HK, Curhan G, Tucker KL, Ascherio A: Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension 50 : 306– 312, 2007
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Froesch ER, Ginsberg JL: Fructose metabolism of adipose tissue. I: Comparison of fructose and glucose metabolism in epididymal adipose tissue of normal rats. J Biol Chem 237 : 3317– 3324, 1962
    OpenUrlFREE Full Text
  19. ↵
    Van den Berghe G: Fructose: Metabolism and short-term effects on carbohydrate and purine metabolic pathways. Prog Biochem Pharmacol 21 : 1– 32, 1986
    OpenUrlPubMed
  20. ↵
    Hallfrisch J: Metabolic effects of dietary fructose. FASEB J 4 : 2652– 2660, 1990
    OpenUrlPubMed
  21. ↵
    Mayes PA: Intermediary metabolism of fructose. Am J Clin Nutr 58 : 754S– 765S, 1993
    OpenUrlPubMed
  22. ↵
    Maenpaa PH, Raivio KO, Kekomaki MP: Liver adenine nucleotides: Fructose-induced depletion and its effect on protein synthesis. Science 161 : 1253– 1254, 1968
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Masson S, Henriksen O, Stengaard A, Thomsen C, Quistorff B: Hepatic metabolism during constant infusion of fructose: Comparative studies with 31P-magnetic resonance spectroscopy in man and rats. Biochim Biophys Acta 1199 : 166– 174, 1994
    OpenUrlPubMed
  24. ↵
    Asipu A, Hayward BE, O'Reilly J, Bonthron DT: Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes 52 : 2426– 2432, 2003
    OpenUrlAbstract/FREE Full Text
  25. Kozak M, Hayward B, Borek D, Bonthron DT, Jaskolski M: Expression, purification and preliminary crystallographic studies of human ketohexokinase. Acta Crystallogr D Biol Crystallogr 57 : 586– 588, 2001
    OpenUrlCrossRefPubMed
  26. ↵
    Bais R, James HM, Rofe AM, Conyers RA: The purification and properties of human liver ketohexokinase: A role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. Biochem J 230 : 53– 60, 1985
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Burch HB, Choi S, Dence CN, Alvey TR, Cole BR, Lowry OH: Metabolic effects of large fructose loads in different parts of the rat nephron. J Biol Chem 255 : 8239– 8244, 1980
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Gersch MS, Mu W, Cirillo P, Reungjui S, Zhang L, Roncal C, Sautin YY, Johnson RJ, Nakagawa T: Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 293 : F1256– F1261, 2007
    OpenUrlCrossRefPubMed
  29. ↵
    Skeel A, Yoshimura T, Showalter SD, Tanaka S, Appella E, Leonard EJ: Macrophage stimulating protein: Purification, partial amino acid sequence, and cellular activity. J Exp Med 173 : 1227– 1234, 1991
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H: Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58 : 1492– 1499, 2000
    OpenUrlCrossRefPubMed
  31. ↵
    Viedt C, Orth SR: Monocyte chemoattractant protein-1 (MCP-1) in the kidney: Does it more than simply attract monocytes? Nephrol Dial Transplant 17 : 2043– 2207, 2002
    OpenUrlCrossRefPubMed
  32. ↵
    Vincent MF, Van den Berghe G, Hers HG: Increase in phosphoribosyl pyrophosphate induced by ATP and Pi depletion in hepatocytes. FASEB J 3 : 1862– 1867, 1989
    OpenUrlPubMed
  33. ↵
    Burch HB, Lowry OH, Meinhardt L, Max P Jr, Chyu K: Effect of fructose, dihydroxyacetone, glycerol, and glucose on metabolites and related compounds in liver and kidney. J Biol Chem 245 : 2092– 2102, 1970
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41 : 1287– 1293, 2003
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Sugaya T, Ruiz-Ortega M, Egido J, Tomino Y: Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal 7 : 1261– 1268, 2005
    OpenUrlCrossRefPubMed
  36. ↵
    Bode JC, Zelder O, Rumpelt HJ, Wittkamp U: Depletion of liver adenosine phosphates and metabolic effects of intravenous infusion of fructose or sorbitol in man and in the rat. Eur J Clin Invest 3 : 436– 441, 1973
    OpenUrlCrossRefPubMed
  37. ↵
    Morris RC Jr, Nigon K, Reed EB: Evidence that the severity of depletion of inorganic phosphate determines the severity of the disturbance of adenine nucleotide metabolism in the liver and renal cortex of the fructose-loaded rat. J Clin Invest 61 : 209– 220, 1978
    OpenUrlCrossRefPubMed
  38. ↵
    Kawasaki T, Akanuma H, Yamanouchi T: Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care 25 : 353– 357, 2002
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Macdonald I, Keyser A, Pacy D: Some effects, in man, of varying the load of glucose, sucrose, fructose, or sorbitol on various metabolites in blood. Am J Clin Nutr 31 : 1305– 1311, 1978
    OpenUrlFREE Full Text
  40. ↵
    Sugawara-Yokoo M, Suzuki T, Matsuzaki T, Naruse T, Takata K: Presence of fructose transporter GLUT5 in the S3 proximal tubules in the rat kidney. Kidney Int 56 : 1022– 1028, 1999
    OpenUrlCrossRefPubMed
  41. ↵
    Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13 : 806– 816, 2002
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Heinz F, Schlegel F, Krause PH: Enzymes of fructose metabolism in human kidney. Enzyme 19 : 85– 92, 1975
    OpenUrlPubMed
  43. ↵
    Pontrelli P, Ursi M, Ranieri E, Capobianco C, Schena FP, Gesualdo L, Grandaliano G: CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: Role of NF-kappaB and lyn. J Am Soc Nephrol 17 : 627– 636, 2006
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Roncal CA, Mu W, Croker B, Reungjui S, Ouyang X, Tabah-Fisch I, Johnson RJ, Ejaz AA: Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 292 : F116– F122, 2007
    OpenUrlCrossRefPubMed
  45. ↵
    Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, Cros G, Azay J: Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 179 : 43– 49, 2005
    OpenUrlCrossRefPubMed
  46. ↵
    Stirpe F, Della Corte E, Bonetti E, Abbondanza A, Abbati A, De Stefano F: Fructose-induced hyperuricaemia. Lancet 2 : 1310– 1311, 1970
    OpenUrlCrossRefPubMed
  47. ↵
    Galbusera C, Orth P, Fedida D, Spector T: Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 71 : 1747– 1752, 2006
    OpenUrlCrossRefPubMed
  48. ↵
    Spector T: Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol 37 : 349– 352, 1988
    OpenUrlCrossRefPubMed
  49. ↵
    Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293 : C584– C596, 2007
    OpenUrlCrossRefPubMed
  50. ↵
    Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B: HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45 : 48– 57, 1994
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 20 (3)
Journal of the American Society of Nephrology
Vol. 20, Issue 3
March 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells
Pietro Cirillo, Michael S. Gersch, Wei Mu, Philip M. Scherer, Kyung Mee Kim, Loreto Gesualdo, George N. Henderson, Richard J. Johnson, Yuri Y. Sautin
JASN Mar 2009, 20 (3) 545-553; DOI: 10.1681/ASN.2008060576

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells
Pietro Cirillo, Michael S. Gersch, Wei Mu, Philip M. Scherer, Kyung Mee Kim, Loreto Gesualdo, George N. Henderson, Richard J. Johnson, Yuri Y. Sautin
JASN Mar 2009, 20 (3) 545-553; DOI: 10.1681/ASN.2008060576
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • RESULTS
    • DISCUSSION
    • CONCISE METHODS
    • DISCLOSURES
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Changes in NAD and Lipid Metabolism Drive Acidosis-Induced Acute Kidney Injury
  • Renal AAV2-Mediated Overexpression of Long Non-Coding RNA H19 Attenuates Ischemic Acute Kidney Injury Through Sponging of microRNA-30a-5p
  • NBCn1 Increases NH4+ Reabsorption Across Thick Ascending Limbs, the Capacity for Urinary NH4+ Excretion, and Early Recovery from Metabolic Acidosis
Show more Basic Research

Cited By...

  • Increased ketohexokinase-A governs fructose-induced podocyte hypertrophy by IL-6/STAT3 signaling activation
  • Fructose Production and Metabolism in the Kidney
  • Perspective: A Historical and Scientific Perspective of Sugar and Its Relation with Obesity and Diabetes
  • Activation of Renal (Pro)Renin Receptor Contributes to High Fructose-Induced Salt Sensitivity
  • Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors
  • Adiponectin Resistance and Proinflammatory Changes in the Visceral Adipose Tissue Induced by Fructose Consumption via Ketohexokinase-Dependent Pathway
  • Endogenous Fructose Production and Fructokinase Activation Mediate Renal Injury in Diabetic Nephropathy
  • Sweet Debate: Fructose versus Glucose in Diabetic Kidney Disease
  • The role of uric acid in the pathogenesis of human cardiovascular disease
  • What Are the Key Arguments Against Uric Acid as a True Risk Factor for Hypertension?
  • Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress: POTENTIAL ROLE IN FRUCTOSE-DEPENDENT AND -INDEPENDENT FATTY LIVER
  • Onco-Nephrology: Tumor Lysis Syndrome
  • Carbohydrate Nutrition Is Associated with the 5-Year Incidence of Chronic Kidney Disease
  • The Effect of Fructose on Renal Biology and Disease
  • Dietary Fructose Inhibits Intestinal Calcium Absorption and Induces Vitamin D Insufficiency in CKD
  • The Not-so-Sweet Side of Fructose
  • Google Scholar

Similar Articles

Related Articles

  • The Not-so-Sweet Side of Fructose
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire